Specialist and Primary Care Treatment of Hepatitis C Infections in US Medicaid in 2018.
作者信息
Kapadia Shashi N, Zhang Hao, Gonzalez Christopher J, Sen Bisakha, Franco Ricardo A, Shapiro Martin F, Bao Yuhua
机构信息
Division of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA.
Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
出版信息
J Gen Intern Med. 2023 Apr;38(5):1323-1325. doi: 10.1007/s11606-022-07860-3. Epub 2022 Nov 2.
Abstract
摘要
相似文献
1
Specialist and Primary Care Treatment of Hepatitis C Infections in US Medicaid in 2018.
J Gen Intern Med. 2023 Apr;38(5):1323-1325. doi: 10.1007/s11606-022-07860-3. Epub 2022 Nov 2.
2
Characteristics of Persons Treated for Hepatitis C Using National Pharmacy Claims Data, United States, 2014-2020.
Clin Infect Dis. 2022 Sep 29;75(6):1078-1080. doi: 10.1093/cid/ciac139.
3
A National Hepatitis C Elimination Program in the United States: A Historic Opportunity.
JAMA. 2023 Apr 18;329(15):1251-1252. doi: 10.1001/jama.2023.3692.
4
Vital Signs: Hepatitis C Treatment Among Insured Adults - United States, 2019-2020.
MMWR Morb Mortal Wkly Rep. 2022 Aug 12;71(32):1011-1017. doi: 10.15585/mmwr.mm7132e1.
5
The Road to Hepatitis C Virus Cure: Practical Considerations from a Health System's Perspective.
Infect Dis Clin North Am. 2018 Jun;32(2):481-493. doi: 10.1016/j.idc.2018.02.007.
6
State Medicaid Restrictions for Direct-Acting Antiviral Therapy Do Not Impact Posttransplant Outcomes of Recipients of Hepatitis C Virus-Viremic Livers.
Liver Transpl. 2021 Jan;27(1):140-143. doi: 10.1002/lt.25902. Epub 2020 Oct 24.
7
State Medicaid Hepatitis C Treatment Eligibility Criteria and Use of Direct-Acting Antivirals.
Clin Infect Dis. 2018 May 2;66(10):1618-1620. doi: 10.1093/cid/cix1062.
8
New Treatments Have Changed the Game: Hepatitis C Treatment in Primary Care.
Infect Dis Clin North Am. 2018 Jun;32(2):313-322. doi: 10.1016/j.idc.2018.02.012.
9
Hepatitis C Treatment Initiation Among US Medicaid Enrollees.
JAMA Netw Open. 2023 Aug 1;6(8):e2327326. doi: 10.1001/jamanetworkopen.2023.27326.
10
Medicaid Subscription-Based Payment Models and Implications for Access to Hepatitis C Medications.
JAMA Health Forum. 2021 Aug 27;2(8):e212291. doi: 10.1001/jamahealthforum.2021.2291. eCollection 2021 Aug.
引用本文的文献
1
Approaches to Offering Hepatitis C Treatment at Syringe Services Programs in the United States: A Scoping Review.
Open Forum Infect Dis. 2025 Apr 8;12(4):ofaf211. doi: 10.1093/ofid/ofaf211. eCollection 2025 Apr.
2
Hepatitis C Treatment in Kentucky Medicaid Recipients with Concurrent Opioid Use Disorder: A Cross-Sectional Study.
J Gen Intern Med. 2025 Jan 21. doi: 10.1007/s11606-025-09356-2.
3
United States Provider Experiences With Telemedicine for Hepatitis C Treatment: A Nationwide Survey.
J Viral Hepat. 2024 Dec;31(12):873-879. doi: 10.1111/jvh.14010. Epub 2024 Oct 1.
4
The State of Hepatitis C Elimination from the Front Lines: A Qualitative Study of Provider-Perceived Gaps to Treatment Initiation.
J Gen Intern Med. 2024 Sep;39(12):2268-2276. doi: 10.1007/s11606-024-08807-6. Epub 2024 May 23.
本文引用的文献
1
Hepatitis C Treatment by Nonspecialist Providers in the Direct-acting Antiviral Era.
Med Care. 2021 Sep 1;59(9):795-800. doi: 10.1097/MLR.0000000000001573.
2
Specialty care access for Medicaid enrollees in expansion states.
Am J Manag Care. 2019 Mar 1;25(3):e83-e87.
3
Trends in Treatment Uptake and Provider Specialty for Hepatitis C Virus (HCV) Infection in the Veterans Affairs Healthcare System: Results From the Electronically Retrieved Cohort of HCV-Infected Veterans (ERCHIVES).
Clin Infect Dis. 2019 Feb 15;68(5):857-859. doi: 10.1093/cid/ciy697.
4
Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014.
Am J Public Health. 2018 Feb;108(2):175-181. doi: 10.2105/AJPH.2017.304132. Epub 2017 Dec 21.
Zotero 插件